Page last updated: 2024-11-03

prazosin and Nerve Degeneration

prazosin has been researched along with Nerve Degeneration in 3 studies

Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.

Nerve Degeneration: Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.

Research Excerpts

ExcerptRelevanceReference
"A novel model of hypertension recently developed in our laboratory shows that neonatal degeneration of capsaicin-sensitive sensory nerves renders a rat responsive to a salt load with a significant rise in blood pressure."3.70Antihypertensive mechanisms underlying a novel salt-sensitive hypertensive model induced by sensory denervation. ( Li, J; Wang, DH, 1999)
"We found slower disease progression, decreased PD-related complications, and a reduced frequency of PD diagnoses in individuals taking TZ and related drugs."1.51Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases. ( Cai, R; Chen, Z; Consiglio, A; Fernandez-Carasa, I; Gao, L; Han, Y; Ji, X; Li, Y; Liu, L; Narayanan, NS; Polgreen, PM; Raya, A; Schultz, JL; Simmering, JE; Su, W; Welsh, MJ; Yuan, Y; Zhang, Y; Zhao, C, 2019)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (33.33)18.2507
2000's1 (33.33)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cai, R1
Zhang, Y1
Simmering, JE1
Schultz, JL1
Li, Y1
Fernandez-Carasa, I1
Consiglio, A1
Raya, A1
Polgreen, PM1
Narayanan, NS1
Yuan, Y1
Chen, Z1
Su, W1
Han, Y1
Zhao, C1
Gao, L1
Ji, X1
Welsh, MJ1
Liu, L1
Muñoz, A1
Lopez-Real, A1
Labandeira-Garcia, JL1
Guerra, MJ1
Wang, DH1
Li, J1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
a Randomized, Double Blind, Placebo Controlled Clinical Trial Exploring the Target Engagement and Tolerability of Terazosin Hydrochloride in Patients With Dementia With Lewy Bodies[NCT04760860]Phase 1/Phase 240 participants (Anticipated)Interventional2024-10-31Not yet recruiting
The Effect of alpha1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: A Follow up Study[NCT05109364]Phase 215 participants (Anticipated)Interventional2022-09-23Recruiting
Assessing Target Engagement of Terazosin in Healthy Adults[NCT04551040]Phase 118 participants (Anticipated)Interventional2021-03-26Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

3 other studies available for prazosin and Nerve Degeneration

ArticleYear
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
    The Journal of clinical investigation, 2019, 10-01, Volume: 129, Issue:10

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros

2019
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
    The Journal of clinical investigation, 2019, 10-01, Volume: 129, Issue:10

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros

2019
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
    The Journal of clinical investigation, 2019, 10-01, Volume: 129, Issue:10

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros

2019
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
    The Journal of clinical investigation, 2019, 10-01, Volume: 129, Issue:10

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros

2019
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
    The Journal of clinical investigation, 2019, 10-01, Volume: 129, Issue:10

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros

2019
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
    The Journal of clinical investigation, 2019, 10-01, Volume: 129, Issue:10

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros

2019
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
    The Journal of clinical investigation, 2019, 10-01, Volume: 129, Issue:10

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros

2019
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
    The Journal of clinical investigation, 2019, 10-01, Volume: 129, Issue:10

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros

2019
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
    The Journal of clinical investigation, 2019, 10-01, Volume: 129, Issue:10

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros

2019
Interaction between the noradrenergic and serotonergic systems in locomotor hyperactivity and striatal expression of Fos induced by amphetamine in rats.
    Experimental brain research, 2003, Volume: 153, Issue:1

    Topics: Adrenergic alpha-Antagonists; Amphetamine; Animals; Behavior, Animal; Central Nervous System Stimula

2003
Antihypertensive mechanisms underlying a novel salt-sensitive hypertensive model induced by sensory denervation.
    Hypertension (Dallas, Tex. : 1979), 1999, Volume: 33, Issue:1 Pt 2

    Topics: Animals; Animals, Newborn; Antihypertensive Agents; Blood Pressure; Body Weight; Calcitonin Gene-Rel

1999